Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization's Stop TB Department

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation today announced a collaboration with the World Health Organization's (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo. These five countries collectively represented more than 13 percent of global TB and more than one-third of the TB/HIV co-infection burden in 2009.

The initiative is expected to be a catalyst in boosting the meaningful engagement of non-governmental and community organizations, a key objective in the WHO's Stop TB strategy, and will draw on technical assistance through community care experts from the Bristol-Myers Squibb Foundation's SECURE THE FUTURE® program.

"Bristol-Myers Squibb's commitment to help communities prevail over serious diseases is embodied in our Foundation's mission to address health disparities and empower communities," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "The hallmark of the Bristol-Myers Squibb Foundation's SECURE THE FUTURE® program is strengthening capacity in local communities. Our work in TB and HIV co-infection has demonstrated the positive impact that community support can have on tracking, follow-up of results and treatment for infected individuals."

The WHO will use its facilitation and brokering role with National TB and AIDS Control Programs to scale up community TB care in the five countries through strengthened engagement of non-governmental (NGOs) and community based organizations. WHO will promote the development of policies and programs that will enable greater involvement of NGOs and civil society organizations in TB community care and the creation of a more cost-effective and sustainable TB response.

This initiative offers a unique opportunity in partnership with SECURE THE FUTURE® to enhance the earlier detection of people with TB to ensure they are treated successfully, and have better access to TB services, especially in HIV prevalent settings. TB services will be strengthened and improved by embracing the advantages that NGOs can bring, such as access to remote areas and a better understanding of local needs, especially among vulnerable groups.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

SECURE THE FUTURE® is the flag ship initiative of the Bristol-Myers Squibb Foundation. Since 1999, Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation have committed $160 million to develop sustainable solutions for vulnerable populations, including women and children infected and affected by HIV/AIDS in Africa. Since its inception, the initiative has provided support for more than 240 projects focused on community education, outreach, medical care and research in 19 countries.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...